

WEST Search History

DATE: Friday, May 30, 2003

Set Name Query
side by side**Hit Count Set Name**
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

| | | | |
|-----|---|------|-----|
| L10 | L8 and lda | 0 | L10 |
| L9 | L8 and lithiodiisopropylamine | 0 | L9 |
| L8 | L6 and glucose | 83 | L8 |
| L7 | L6 and uracil | 1 | L7 |
| L6 | L5 and (saccharid\$5 or sugar or carbohydrate) | 111 | L6 |
| L5 | L4 and ceramide | 120 | L5 |
| L4 | L1 and (tumor or cancer) | 1243 | L4 |
| L3 | ((((514/23 514/25 514/27)!.CCLS. (536/1.11 536/4.1)!.CCLS. (544/1 544/224 544/242)!.CCLS.)) | 5494 | L3 |

DB=USPT; PLUR=YES; OP=ADJ

| | | | |
|----|--|------|----|
| L2 | L1 and (tumor or cancer) | 1243 | L2 |
| L1 | ((514/23 514/25 514/27)!.CCLS. (536/1.11 536/4.1)!.CCLS. (544/1 544/224 544/242)!.CCLS.) | 4546 | L1 |

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 18:11:11 ON 30 MAY 2003)

FILE 'REGISTRY' ENTERED AT 18:11:21 ON 30 MAY 2003

L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 1213 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:12:26 ON 30 MAY 2003

FILE 'CAPLUS, USPATFULL, MEDLINE' ENTERED AT 18:12:40 ON 30 MAY 2003

L4 1158 S L3
L5 2 S L3 AND CERAMIDE
L6 105 S L3 AND (CANCER OR TUMOR)
L7 10 S L6 AND (SACCHARID? OR SUGAR OR CARBOHYDRATE)

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:521462 CAPLUS
 DOCUMENT NUMBER: 137:88442
 TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms
 INVENTOR(S): Shanahan-Pendergast, Elisabeth
 PATENT ASSIGNEE(S): Ire.
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2002053138 | A2 | 20020711 | WO 2002-IE1 | 20020102 |
| WO 2002053138 | A3 | 20020919 | | |

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT 1404-64-4, Sparsomycin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

RN 1404-64-4 CAPLUS

CN 2-Propenamide, N-[(1S)-1-(hydroxymethyl)-2-[(R)-[(methylthio)methyl]sulfinylethyl]-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-, (2E)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:78368 CAPLUS
 DOCUMENT NUMBER: 134:131369
 TITLE: process for the preparation of ceramide analogs and their use as antitumor agents

INVENTOR(S): Macchia, Bruno; Balsamo, Aldo; Macchia, Marco; Del
 Tacca, Mario; Danesi, Romano
 PATENT ASSIGNEE(S): Bracco S.p.A., Italy
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2001007418 | A2 | 20010201 | WO 2000-EP7023 | 20000721 |
| WO 2001007418 | A3 | 20010510 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG IT 1307786 B1 20011119 IT 1999-FI169 19990722 EP 1198458 A2 20020424 EP 2000-956250 20000721 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003505451 T2 20030212 JP 2001-512504 20000721 PRIORITY APPLN. INFO.: IT 1999-FI169 A 19990722 WO 2000-EP7023 W 20000721 OTHER SOURCE(S): MARPAT 134:131369 GI | | | | |



AB The present invention discloses a process for the prepn. of ceramide analog (I; X1, X2 = O, S; R1, R2 = (CH2)13Me, (un)substituted alkyl, (un)substituted alkylene groups with one or more substituents selected among arom., primary, secondary and tertiary aminic, quaternary ammonium, CO2H, OH, polyoxyalkyl and ethereal groups, amino acids, halogen, **saccharidic** portions, providing that between R1 and R2 only one is (CH2)13Me; R3, R4 = H, (un)substituted alkyl, (un)substituted alkylene groups with one or more substituents selected among arom., primary, secondary and tertiary aminic, quaternary ammonium, CO2H, OH, polyoxyalkyl and ethereal groups, amino acids, halogen, **saccharidic** portion) and pharmaceutical formulations for the treatment of **tumors**. Thus, II was prepd. by the reaction of .beta.-ketoester III, Me(CH2)14CH(COCH2Me)COOCH2Me (obtained by the reaction of Et palmitate and propionyl chloride), with thiourea. II shows IC50 of 1.7 .mu.M in tests against human leukemia cell line called CCRF/CEM.


IT **322391-32-2P**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(process for the prepn. of ceramide analogs and their use as antitumor agents)

RN 322391-32-2 CAPLUS

CN 4(1H)-Pyrimidinone, 6-ethyl-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




IT 322391-31-1P 322391-33-3P 322391-34-4P
322391-35-5P 322391-36-6P 322391-37-7P
322391-38-8P 322391-39-9P 322391-40-2P
322391-41-3P 322391-42-4P 322391-43-5P
322391-44-6P 322391-48-0P 322391-51-5P
322391-52-6P 322391-54-8P 322391-55-9P
322391-56-0P 322391-57-1P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the prepn. of ceramide analogs and their use as antitumor agents)


RN 322391-31-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-ethyl-6-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-33-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-ethyl-5-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-34-4 CAPLUS


CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-35-5 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 6-propyl-5-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-36-6 CAPLUS
 CN 4(1H)-Pyrimidinone, 6-butyl-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-37-7 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 6-butyl-5-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-38-8 CAPLUS
 CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(2-methylpropyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-39-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(2-methylpropyl)-5-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-40-2 CAPLUS

CN 4(1H)-Pyrimidinone, 6-(2,2-dimethylpropyl)-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-41-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(2,2-dimethylpropyl)-5-tetradecyl- (9CI) (CA INDEX NAME)




RN 322391-42-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(2-phenylethyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-43-5 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 6-(2-phenylethyl)-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-44-6 CAPLUS
 CN 4(1H)-Pyrimidinone, 6-(3-aminopropyl)-2,3-dihydro-5-tetradecyl-2-thioxo-
 (9CI) (CA INDEX NAME)




RN 322391-48-0 CAPLUS
 CN Glycine, 3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-
 pyrimidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 322391-51-5 CAPLUS
 CN L-Aspartic acid, 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-
 pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322391-52-6 CAPLUS
 CN 4(1H)-Pyrimidinone, 2,3-dihydro-5-tetradecyl-2-thioxo-6-[3-[[3,4,6-tris-O-
 (phenylmethyl)-.beta.-D-glucopyranosyl]oxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322391-54-8 CAPLUS


CN 4(1H)-Pyrimidinone, 6-[3-(.beta.-D-glucopyranosyloxy)propyl]-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 322391-55-9 CAPLUS

CN 4(1H)-Pyrimidinone, 6-(3-bromopropyl)-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-56-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-[3-(1-piperidinyl)propyl]-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 322391-57-1 CAPLUS
 CN 4-Pyrimidinepropanaminium, N,N,N-triethyl-1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-, bromide (9CI) (CA INDEX NAME)




● Br⁻


IT **322391-45-7**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for the prepn. of ceramide analogs and their use as antitumor agents)
 RN 322391-45-7 CAPLUS
 CN 4(1H)-Pyrimidinone, 6-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



IT **10606-53-8P 322391-46-8P 322391-47-9P 322391-49-1P 322391-50-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for the prepn. of ceramide analogs and their use as antitumor agents)
 RN 10606-53-8 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 5-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 322391-46-8 CAPLUS
 CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(3-hydroxypropyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-47-9 CAPLUS


CN Glycine, N-[(phenylmethoxy)carbonyl]-, 3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 322391-49-1 CAPLUS

CN L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322391-50-4 CAPLUS

CN L-Aspartic acid, 4-(1,1-dimethylethyl) 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 10 USPATFULL

ACCESSION NUMBER: 2003:120833 USPATFULL
TITLE: HIV inhibiting pyrimidine derivatives
INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, BELGIUM
De Corte, Bart, Southampton, PA, UNITED STATES
De Jonge, Marc Rene, Tilburg, NETHERLANDS
Heeres, Jan, Vosselaar, BELGIUM
Ho, Chih Yung, Lansdale, PA, UNITED STATES
Janssen, Marcel August Constant, Vosselaar, BELGIUM
Janssen, Paul Adriaan Jan, Vosselaar, BELGIUM
Koymans, Lucien Maria Henricus, Turnhout, BELGIUM
Kukla, Michael Joseph, Maple Glen, PA, UNITED STATES
Ludovici, Donald William, Quakertown, PA, UNITED STATES
Van Aken, Koen Jeanne Alfons, Turnhout, BELGIUM

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2003083317 | A1 | 20030501 |
| APPLICATION INFO.: | US 2002-185528 | A1 | 20020628 (10) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 2000-749181, filed on 27 Dec 2000, GRANTED, Pat. No. US 6440986 Continuation of Ser. No. US 1999-276360, filed on 25 Mar 1999, GRANTED, Pat. No. US 6197779 | | |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | EP 1998-201587 | 19980514 |
| | EP 1998-203948 | 19981125 |
| | US 1998-79632P | 19980327 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003 | |
| NUMBER OF CLAIMS: | 24 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1867 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns the use of the compounds of formula ##STR1##

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.^{sup.4} or N; n is 0 to 4; Q is hydrogen or --NR.^{sup.1}R.^{sup.2}; R.^{sup.1} and R.^{sup.2} are selected from hydrogen, hydroxy, C.sub.1-12alkyl, C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl, C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12alkyl)-amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl wherein each C.sub.1-12alkyl may optionally be substituted; or R.^{sup.1} and R.^{sup.2} taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; R.^{sup.3} is hydrogen, aryl, C.sub.1-6alkylcarbonyl, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxy-carbonyl,; and R.^{sup.4} is hydroxy, halo, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R.^{sup.5} is hydrogen or C.sub.1-4alkyl; L is optionally substituted C.sub.1-10alkyl, C.sub.3-10alkenyl, C.sub.3-10alkynyl, C.sub.3-7cycloalkyl; or L is --X.^{sup.1}--R.^{sup.6} or --X.^{sup.2}--Alk--R.^{sup.7} wherein R.^{sup.6} and R.^{sup.7} are optionally substituted phenyl; X.^{sup.1} and X.^{sup.2} are --NR.^{sup.3}--, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--; Alk is C.sub.1-4alkanediyl; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and

compositions comprising them.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **244768-09-0P**

(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)

RN 244768-09-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI)
(CA INDEX NAME)



L7 ANSWER 4 OF 10 USPATFULL

ACCESSION NUMBER: 2002:75592 USPATFULL

TITLE: DNA glycosylase inhibitors, and uses related thereto

INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States

Deng, Li, Brookline, MA, United States

PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6369237 | B1 | 20020409 |
| APPLICATION INFO.: | US 1997-812653 | | 19970307 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | GRANTED | | |
| PRIMARY EXAMINER: | Geist, Gary | | |
| ASSISTANT EXAMINER: | Owens, Jr., Howard V. | | |
| LEGAL REPRESENTATIVE: | Gordon, Dana M., Foley, Hoag & Eliot LLP | | |
| NUMBER OF CLAIMS: | 25 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 6 Drawing Figure(s); 4 Drawing Page(s) | | |
| LINE COUNT: | 2136 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to novel inhibitors of DNA glycosylases. The invention is based at least in part on the observation that specific substituted pyrrolidines, and analogs thereof, are capable of specifically inhibiting DNA glycosylases, e.g., as transition state analogs, and consequently are useful for modulation of DNA repair. Such compounds can, for example, be used for treating subjects having a disorder associated with excessive cell proliferation, such as in the treatment of various **cancers**. Furthermore, these glycosylase inhibitors can be used as anti-bacterial, anti-viral and anti-fungal agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **147-61-5DP**, nucleotide derivs. contg.

(DNA glycosylase inhibitors and their therapeutic uses)

RN 147-61-5 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 5-(hydroxymethyl)-6-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 10 USPATFULL

ACCESSION NUMBER: 2001:163203 USPATFULL

TITLE: Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same

INVENTOR(S): Yano, Shingo, Kawagoe, Japan
Tada, Yukio, Higashimatsuyama, Japan
Kazuno, Hideki, Hanno, Japan
Sato, Tsutomu, Hanno, Japan
Yamashita, Junichi, Honjo, Japan
Suzuki, Norihiko, Hidaka, Japan
Emura, Tomohiro, Iruma, Japan
Fukushima, Masakazu, Hanno, Japan
Asao, Tetsuji, Tokorozawa, Japan

PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6294535 | B1 | 20010925 |
| APPLICATION INFO.: | US 1999-457668 | | 19991209 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1998-6009, filed on 12 Jan 1998, now patented, Pat. No. US 6159969 Division of Ser. No. US 737677, now patented, Pat. No. US 5744475 | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1995-71667 | 19950329 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | Truong, Tamthom N. | |
| LEGAL REPRESENTATIVE: | Sughrue, Mion, Zinn, Macpeak & Seas, PLLC | |
| NUMBER OF CLAIMS: | 15 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2156 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel uracil derivatives having excellent inhibiting effects on human derived thymidine phosphorylates and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators and antitumor agents containing such novel compounds, and a process for their preparation and use are described. The novel uracil derivative compounds are represented by the general formula (1'): ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183204-36-6P 183204-37-7P 183204-79-7P
183204-81-1P 183205-13-2P 183205-14-3P


(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183204-36-6 USPATFULL


CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 183204-79-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183204-81-1 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 183205-13-2 USPATFULL
 CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183205-14-3 USPATFULL
 CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 183205-45-0P
 (prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
 RN 183205-45-0 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 10 USPATFULL
 ACCESSION NUMBER: 2001:123586 USPATFULL
 TITLE: HIV inhibiting pyrimidine derivatives
 INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, Belgium
 De Corte, Bart, Southampton, PA, United States
 De Jonge, Marc Rene, CA Tilburg, Netherlands
 Heeres, Jan, Vosselaar, Belgium
 Ho, Chih Yung, Lansdale, PA, United States
 Janssen, Marcel August Constant, Vosselaar, Belgium
 Janssen, Paul Adriaan Jan, Vosselaar, Belgium
 Koymans, Lucien Maria Henricus, Turnhout, Belgium

Kukla, Michael Joseph, Maple Glen, PA, United States
Ludovici, Donald William, Quakertown, PA, United States
Van Aken, Koen Jeanne Alfons, Turnhout, Belgium

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2001011094 | A1 | 20010802 |
| | US 6440986 | B2 | 20020827 |
| APPLICATION INFO.: | US 2000-749181 | A1 | 20001227 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1999-276360, filed on 25 Mar 1999, GRANTED, Pat. No. US 6197779 | | |

| | NUMBER | DATE |
|--|--|---------------|
| PRIORITY INFORMATION: | EP 1998-201587 | 19980514 |
| | EP 1998-203948 | 19981125 |
| | US 1998-79632P | 19980327 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Philip S. Johnson, Esq., Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ, 08933-7003 | |
| NUMBER OF CLAIMS: | 24 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1898 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |
| AB | This invention concerns the use of the compounds of formula ##STR1## | |

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.^{sup.4} or N; n is 0 to 4; Q is hydrogen or --NR.^{sup.1}R.^{sup.2}; R.^{sup.1} and R.^{sup.2} are selected from hydrogen, hydroxy, C.sub.1-12alkyl, C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl, C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12alkyl)amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl wherein each C.sub.1-12alkyl may optionally be substituted; or R.^{sup.1} and R.^{sup.2} taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; R.^{sup.3} is hydrogen, aryl, C.sub.1-6alkylcarbonyl, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl,; and R.^{sup.4} is hydroxy, halo, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R.^{sup.5} is hydrogen or C.sub.1-4alkyl; L is optionally substituted C.sub.1-10alkyl, C.sub.3-10alkenyl, C.sub.3-10alkynyl, C.sub.3-7cycloalkyl; or L is --X.^{sup.1}--R.^{sup.6} or --X.^{sup.2}--Alk--R.^{sup.7} wherein R.^{sup.6} and R.^{sup.7} are optionally substituted phenyl; X.^{sup.1} and X.^{sup.2} are --NR.^{sup.3}--, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--; Alk is C.sub.1-4alkanediyl; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical: for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 244768-09-0P

(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)

RN 244768-09-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI)
(CA INDEX NAME)



L7 ANSWER 7 OF 10 USPATFULL

ACCESSION NUMBER: 2001:102824 USPATFULL

TITLE: Cancerous metastasis inhibitors containing uracil derivatives

INVENTOR(S): Miyadera, Kazutaka, Hanno, Japan
Emura, Tomohiro, Iruma, Japan
Wierzba, Konstanty, Sayama, Japan
Yamada, Yuji, Higashiyamoto, Japan

PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------------------|
| PATENT INFORMATION: | US 6255314 | B1 | 20010703 |
| | WO 9813045 | | 19980402 |
| APPLICATION INFO.: | US 1998-77209 | | 19980526 (9) |
| | WO 1997-JP3355 | | 19970922 |
| | | | 19980526 PCT 371 date |
| | | | 19980526 PCT 102(e) date |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1996-251303 | 19960924 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Raymond, Richard L. | |
| ASSISTANT EXAMINER: | Balasubramanian, Venkataraman | |
| LEGAL REPRESENTATIVE: | Sughrue, Mion, Zinn, Macpeak & Seas, PLLC | |
| NUMBER OF CLAIMS: | 7 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2020 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a drug which has inhibitory activities against thymidine phosphorylase and inhibits metastasis of a **cancer**. Specifically, this invention relates to a cancerous metastasis inhibitor comprising, as an active ingredient, a uracil derivative represented by the following formula (1): ##STR1##

wherein R.sup.1 represents a chlorine, bromine or iodine atom or a cyano or lower alkyl group and R.sup.2 represents a substituted or unsubstituted 4-8 membered hetero-cyclic group having nitrogen atoms or a substituted or unsubstituted amidinothio, guanidino, (lower alkyl)amidino, amino or like group, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 183204-36-6P 183204-37-7P 183204-79-7P

183204-81-1P 183205-13-2P 183205-14-3P


(prepn. of uracil derivs. as cancer metastasis inhibitors)

RN 183204-36-6 USPATFULL


CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 183204-79-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183204-81-1 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 183205-13-2 USPATFULL
 CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183205-14-3 USPATFULL
 CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 183205-45-0P
 (prepn. of uracil derivs. as cancer metastasis inhibitors)
 RN 183205-45-0 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 USPATFULL
 ACCESSION NUMBER: 2001:33276 USPATFULL
 TITLE: HIV inhibiting pyrimidine derivative
 INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, Belgium
 De Corte, Bart, Southampton, PA, United States
 De Jonge, Marc Rene, Tilburg, Netherlands
 Heeres, Jan, Vosselaar, Belgium
 Ho, Chih Yung, Lansdale, PA, United States
 Janssen, Marcel August Constant, Vosselaar, Belgium
 Janssen, Paul Adriaan Jan, Vosselaar, Belgium
 Koymans, Lucien Maria Henricus, Turnhout, Belgium
 Kukla, Michael Joseph, Maple Glen, PA, United States

PATENT ASSIGNEE(S): Ludovici, Donald William, Quakertown, PA, United States
 Van Aken, Koen Jeanne Alfons, Turnhout, Belgium
 Janssen Pharmaceutica, Inc., New Brunswick, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6197779 | B1 | 20010306 |
| APPLICATION INFO.: | US 1999-276360 | | 19990325 (9) |

| | NUMBER | DATE |
|-----------------------|----------------|---------------|
| PRIORITY INFORMATION: | EP 1998-201587 | 19980514 |
| | EP 1998-203948 | 19981125 |
| | US 1998-79632P | 19980327 (60) |

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Liu, Hong
 LEGAL REPRESENTATIVE: Appollina, Mary
 NUMBER OF CLAIMS: 4
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1660

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns the use of the compounds of formula ##STR1##

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR^{sup.4} or N; n is 0 to 4; Q is hydrogen or --NR^{sup.1} R^{sup.2}; R^{sup.1} and R^{sup.2} are selected from hydrogen, hydroxy, C_{sub.1-12} alkyl, C_{sub.1-12} alkyloxy, C_{sub.1-12} alkylcarbonyl, C_{sub.1-12} alkyloxycarbonyl, aryl, amino, mono- or di(C_{sub.1-12} alkyl)amino, mono- or di(C_{sub.1-12} alkyl)aminocarbonyl wherein each C_{sub.1-12} alkyl may optionally be substituted; or R^{sup.1} and R^{sup.2} taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C_{sub.1-12} alkyl)aminoC_{sub.1-4} alkylidene; R^{sup.3} is hydrogen, aryl, C_{sub.1-6} alkylcarbonyl, optionally substituted C_{sub.1-6} alkyl, C_{sub.1-6} alkyloxycarbonyl,; and R^{sup.4} is hydroxy, halo, optionally substituted C_{sub.1-6} alkyl, C_{sub.1-6} alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R^{sup.5} is hydrogen or C_{sub.1-4} alkyl; L is optionally substituted C_{sub.1-10} alkyl, C_{sub.3-10} alkenyl, C_{sub.3-10} alkynyl, C_{sub.3-7} cycloalkyl; or L is --X^{sup.1} --R^{sup.6} or --X^{sup.2} --Alk--R^{sup.7} wherein R^{sup.6} and R^{sup.7} are optionally substituted phenyl; X^{sup.1} and X^{sup.2} are --NR^{sup.3} --, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --; Alk is C_{sub.1-4} alkanediyl; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 244768-09-0P

(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)

RN 244768-09-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI)
 (CA INDEX NAME)



L7 ANSWER 9 OF 10 USPATFULL

ACCESSION NUMBER: 2000:168016 USPATFULL

TITLE: Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same

INVENTOR(S): Yano, Shingo, Kawagoe, Japan
Tada, Yukio, Higashimatsuyama, Japan
Kazuno, Hideki, Hanno, Japan
Sato, Tsutomu, Hanno, Japan
Yamashita, Junichi, Honjo, Japan
Suzuki, Norihiko, Hidaka, Japan
Emura, Tomohiro, Iruma, Japan
Fukushima, Masakazu, Hanno, Japan
Asao, Tetsuji, Tokorozawa, Japan

PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6159969 | | 20001212 |
| APPLICATION INFO.: | US 1998-6009 | | 19980112 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1996-737677, filed on 21 Nov 1996, now patented, Pat. No. US 5744475 | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1995-71667 | 19950329 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | Truong, Tamthom N. | |
| LEGAL REPRESENTATIVE: | Sughrue, Mion, Zinn, Macpeak & Seas, PLLC | |
| NUMBER OF CLAIMS: | 14 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2555 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described. The novel compounds satisfy the general formula (1): ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183204-36-6P 183204-37-7P 183204-79-7P
183204-81-1P 183205-13-2P 183205-14-3P


(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183204-36-6 USPATFULL


CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 183204-79-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183204-81-1 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 183205-13-2 USPATFULL
 CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL

CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 183205-45-0P

(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183205-45-0 USPATFULL

CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 10 USPATFULL

ACCESSION NUMBER: 1998:45210 USPATFULL

TITLE: Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same

INVENTOR(S): Yano, Shingo, Kawagoe, Japan
Tada, Yukio, Higashimatsuyama, Japan
Kazuno, Hideki, Hanno, Japan
Sato, Tsutomu, Hanno, Japan
Yamashita, Junichi, Honjo, Japan
Suzuki, Norihiko, Hidaka, Japan
Emura, Tomohiro, Iruma, Japan
Fukushima, Masakazu, Hanno, Japan

PATENT ASSIGNEE(S): Asao, Tetsuji, Tokorozawa, Japan
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------------------|
| PATENT INFORMATION: | US 5744475 | | 19980428 |
| | WO 9630346 | | 19961003 |
| APPLICATION INFO.: | US 1996-737677 | | 19961121 (8) |
| | WO 1996-JP828 | | 19960328 |
| | | | 19961121 PCT 371 date |
| | | | 19961121 PCT 102(e) date |


| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1995-71667 | 19950329 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | Ngo, Tamthom T. | |
| LEGAL REPRESENTATIVE: | Sughrue, Mion, Zinn, Macpeak & Seas, PLLC | |
| NUMBER OF CLAIMS: | 14 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2388 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described. The novel compounds satisfy the general formula (1): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 183204-36-6P 183204-37-7P 183204-79-7P
183204-81-1P 183205-13-2P 183205-14-3P
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
RN 183204-36-6 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 183204-79-7 USPATFULL
 CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 183204-81-1 USPATFULL
 CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 183205-13-2 USPATFULL
 CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL

CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 183205-45-0P

(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183205-45-0 USPATFULL

CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



=>